Trial reportArthritis care & research2026
Exploring Patients' Profiles Associated With the Resolution of Acute Calcium Pyrophosphate Arthritis Treated With Colchicine and Prednisone: Post Hoc Analysis of a Randomized Controlled Trial.
Trial report in Arthritis care & research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03128905 (Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Colchicine or Prednisone for the Treatment of Acute Calcium Pyrophosphate Deposition (CPPD) Arthritis: Open-label, Randomized, Multicenter, Equivalence Trial of Efficacy and Safety
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
objectiveThe objective was to identify factors determining acute arthritis resolution and safety with colchicine and prednisone in acute calcium pyrophosphate (CPP) crystal arthritis.
methodsWe conducted a post hoc analysis of the COLCHICORT trial, which compared colchicine and prednisone for the treatment of acute CPP crystal arthritis, using a composite outcome of secondary endpoints of the primary analysis. Factors associated with the sustained arthritis resolution with prednisone or colchicine treatment on day three, and the occurrence of gastrointestinal adverse events (AEs) with colchicine, were examined. Two different machine-learning approaches were used to identify independent factors associated with the efficacy outcome: multiple logistic regressions and a decision tree were used.
resultsIn total, 43 of 89 (48.3%) of participants were considered definite responders. In univariable analysis, definitive responders were more often hospitalized for stroke (9 of 43; P = 0.04), had an age ≥80 years old (39 of 43; P = 0.045), and were dyslipidemic (25 of 43; P = 0.03), whereas poor responders were more commonly hospitalized to manage the acute arthritis episode (22 of 43; P < 0.001) In multiple logistic regression, acute arthritis of the wrists (odds ratio [OR] 4.06, 95% confidence interval [CI] 1.21-15.50.85) were associated with arthritis resolution on day three, whereas randomization in the colchicine arm (OR 0.31, 95% CI 0.11-0.83) and diuretic use (OR 0.23, 95% CI 0.097-0.95) were associated with a poor treatment response. Hospital admission for acute arthritis, C-reactive protein levels, and estimated glomerular filtration rate were decision tree nodes selected as crucial for predicting definitive flare resolution. Three candidate variables were identified in the multiple logistic regression model explaining the occurrence of gastrointestinal AEs with colchicine: male sex (OR 0.33, 95% CI 0.07-1.29) and diabetes (OR 0.24, 95% CI 0.030-1.24) seemed protective, whereas statin use (OR 3.54, 95% CI 0.83-18.82) seemed associated with their occurrence.
conclusionThis study identified factors associated with the definitive response to colchicine and prednisone treatment in acute CPP crystal arthritis. Colchicine was associated with poorer efficacy and was impacted by a dual effect on its safety and efficacy by medications and associated conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.